user
menu
letter
Sign InRegister
langEnglisharrow

Human EFEMP1 Protein, His Tag

Cat. No. / Size
Price
Availability
Qty
EF1-H5243-100ug
$435.00
In Stock - Delivery in 1-2 business days
EF1-H5243-1mg (500ug X 2)
$2,575.00
In Stock - Delivery in 2 weeks
EF1-H5243
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
Request Quote
Product Details
Performance Data
Reviews & Citations
Resources
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

EFEMP1

Source

Human EFEMP1 Protein, His Tag (EF1-H5243) is expressed from human 293 cells (HEK293). It contains AA Gln 18 - Phe 493 (Accession # Q12805).

Predicted N-terminus: His

Molecular Characterization
Other Tags and Version Biotin & Other Labeled Version

This protein carries a polyhistidine tag at the N-terminus.

The protein has a calculated MW of 54.6 kDa. The protein migrates as 53-58 kDa and 60-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System

Background

EFEMP1, also known as fibulin-3, is a secreted glycoprotein in the fibulin family. It binds EGFR and activates downstream signaling (e.g., PI3K/AKT). Overexpressed in cancers like glioblastoma, it promotes malignancy and immunosuppression. As an emerging drug target, blocking antibodies and engineered protein variants (e.g., ZR30) are under development to inhibit tumor growth and angiogenesis, offering promising therapeutic potential.